Convergent Therapeutics Inc., a US-based clinical-stage biotechnology company, announced on Wednesday that it has named Eric M Sullivan as its new chief financial officer.

Sullivan has more than 20 years of finance and operations experience in the biotechnology industry, working on financial management, strategic planning, and fundraising and capital market transactions across the public and private markets. He has served as chief financial officer at TCR2 Therapeutics via the completion of the acquisition by Adaptimmune Therapeutics. He has also served as president and chief financial officer at Triplet Therapeutics. He has also served in the senior management positions at Gemini Therapeutics, Oncorus, bluebird bio, Merrimack Pharmaceuticals and PwC.

Sullivan has a BS in Accountancy from Bentley University and is also a Certified Public Accountant.